Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Advanced Biomed Inc.
ADVB
Other
Use Of Proceeds Disclosure
Amendment Modification Waiver Clause
New York Jurisdiction Clause
Corporate Authority Representation
Other
Financing Activities Cash Flow Disclosure
Nol Carryforward Expiration Disclosure
Institutional Investment
Cash Flow Statement Investing Activities
Reverse Stock Split Effected
Nol Tax Credit Carryforward
Net Loss Reported
No Icfr Changes In Quarter
Codm Segment Reporting Disclosure
Material Weakness Internal Controls
Valuation Allowance Deferred Tax Disclosure
Ipo Or Capital Raising Completion
Critical Accounting Policies Disclosure
Core
Enrollment Failure
Other
Corporate Organization And Standing Representation
New York Jurisdiction Clause
Amendment Modification Waiver Clause
No Broker Fees Representation
Sanctions Compliance Representation
Closing Deliverables Specified
Fcpa Compliance Representation
Regulation D Offering Disclosure
Coinvestment Exemptive Order Requested
Institutional Investment
Tax Advisor Consultation Urged
Corporate Authority Representation
Investment Company Act Exemption Claimed
Restricted Stock Certificate Legend Required
Survival Of Representations Warranties Clause
Other
Board Fairness Determination
Corporate Authority Representation
Equity Plan Board Approval Conditional On Shareholder Vote
Other
Reverse Stock Split Effected
Nasdaq Minimum Bid Price Delisting Notice
Other
New York Jurisdiction Clause
Corporate Organization And Standing Representation
Closing Deliverables Specified
Corporate Authority Representation
Amendment Modification Waiver Clause
Non Assignment Clause
Board Fairness Determination
Director Officer Indemnification Provision
Confidential Information Return Obligation
Ai Diagnostics Investment
No Broker Fees Representation
Ip Assignment To Company
Equity Plan Board Approval Conditional On Shareholder Vote
Conflicted Defense Counsel Provision
Indemnification Consent Requirement
Other
Net Loss Reported
Cash Flow Statement Investing Activities
Administrative Efficiency
Financing Activities Cash Flow Disclosure
No Icfr Changes In Quarter
Codm Segment Reporting Disclosure
Material Weakness Internal Controls
Foreign Currency Translation Accounting Disclosure
Burn Rate Controlled
Valuation Allowance Deferred Tax Disclosure
Prc Overseas Listing Regulatory Disclosure
Critical Accounting Policies Disclosure
Core
Enrollment Failure
Lead Asset Progress
Biotech v3
Ind Submission Planned